0.7756
Schlusskurs vom Vortag:
$0.8024
Offen:
$0.7968
24-Stunden-Volumen:
1.22M
Relative Volume:
0.28
Marktkapitalisierung:
$23.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.0507
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
+23.37%
1M Leistung:
+190.49%
6M Leistung:
-55.68%
1J Leistung:
-80.80%
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MBRX
Moleculin Biotech Inc
|
0.7756 | 18.99M | 0 | -29.77M | -24.23M | -15.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan
Is Moleculin Biotech Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com
Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN
What drives Moleculin Biotech Inc. stock priceAccelerated earnings growth - Autocar Professional
What analysts say about Moleculin Biotech Inc. stockMassive wealth growth - jammulinksnews.com
Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - The Globe and Mail
Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia
Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Canada
Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Nasdaq
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - GlobeNewswire
What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser
Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa
Moleculin Biotech Enters New Stock Offering Agreement - TipRanks
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com
Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire
Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia
Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest
Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq
MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan
Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan
Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st
Several Insiders Invested In Moleculin Biotech Flagging Positive News - Yahoo Finance
Moleculin Biotech (MBRX) Price Target Reduced to $13 by Roth Cap - GuruFocus
Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks
Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest
Moleculin Biotech Raises $5.9M in Public Offering - TipRanks
Health Care Stocks Stumble Amid Market Adjustments - Finimize
Moleculin Biotech's $5.9M Financing: A Lifeline for Annamycin or a Risky Gamble? - AInvest
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
Moleculin Biotech's 48% Plunge: Technical Sell-Off or Sector Sentiment Shift? - AInvest
Moleculin Biotech (NASDAQ:MBRX) Given Buy Rating at HC Wainwright - Defense World
Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire
Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus
Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks
Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):